Chao Xie1,2, Ting Guo2, Wei Wang1, Gang Li1, Zhou Cai1, Shen Chen1, Xianwei Wang3, Ziyu Liu4, Zuyong Wang5. 1. Department of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. 2. College of Materials Science and Engineering, Hunan University, Changsha, 410072, People's Republic of China. 3. Department of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. wangxianweilq@163.com. 4. College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China. lzytcm@163.com. 5. College of Materials Science and Engineering, Hunan University, Changsha, 410072, People's Republic of China. wangzy@hnu.edu.cn.
Abstract
BACKGROUND: Vascular intimal hyperplasia (IH) is one of the key challenges in the clinical application of small-diameter vascular grafts. Current tissue engineering strategies focus on vascularization and antithrombotics, yet few approaches have been developed to treat IH. Here, we designed a tissue-engineered vascular scaffold with portulaca flavonoid (PTF) composition and biomimetic architecture. METHOD: By electrospinning, PTF is integrated with biodegradable poly(ε-caprolactone) (PCL) into a bionic vascular scaffold. The structure and functions of the scaffolds were evaluated based on material characterization and cellular biocompatibility. Human vascular smooth muscle cells (HVSMCs) were cultured on scaffolds for up to 14 days. RESULTS: The incorporation of PTF and preparation parameters during fabrication influences the morphology of the scaffold, including fibre diameter, structure, and orientation. Compared to the PCL scaffold, the scaffolds integrated with bioactive PTF show better hydrophilicity and degradability. HVSMCs seeded on the scaffold alongside the fibres exhibit fusiform-like shapes, indicating that the scaffold can provide contact guidance for cell morphology alterations. This study demonstrates that the PCL/PTF (9.1%) scaffold inhibits the excessive proliferation of HVSMCs without causing cytotoxicity. CONCLUSION: The study provides insights into the problem of restenosis caused by IH. This engineered vascular scaffold with complex function and preparation is expected to be applied as a substitute for small-diameter vascular grafts.
BACKGROUND: Vascular intimal hyperplasia (IH) is one of the key challenges in the clinical application of small-diameter vascular grafts. Current tissue engineering strategies focus on vascularization and antithrombotics, yet few approaches have been developed to treat IH. Here, we designed a tissue-engineered vascular scaffold with portulaca flavonoid (PTF) composition and biomimetic architecture. METHOD: By electrospinning, PTF is integrated with biodegradable poly(ε-caprolactone) (PCL) into a bionic vascular scaffold. The structure and functions of the scaffolds were evaluated based on material characterization and cellular biocompatibility. Human vascular smooth muscle cells (HVSMCs) were cultured on scaffolds for up to 14 days. RESULTS: The incorporation of PTF and preparation parameters during fabrication influences the morphology of the scaffold, including fibre diameter, structure, and orientation. Compared to the PCL scaffold, the scaffolds integrated with bioactive PTF show better hydrophilicity and degradability. HVSMCs seeded on the scaffold alongside the fibres exhibit fusiform-like shapes, indicating that the scaffold can provide contact guidance for cell morphology alterations. This study demonstrates that the PCL/PTF (9.1%) scaffold inhibits the excessive proliferation of HVSMCs without causing cytotoxicity. CONCLUSION: The study provides insights into the problem of restenosis caused by IH. This engineered vascular scaffold with complex function and preparation is expected to be applied as a substitute for small-diameter vascular grafts.
Authors: Victor Aboyans; Jean-Baptiste Ricco; Marie-Louise E L Bartelink; Martin Björck; Marianne Brodmann; Tina Cohnert; Jean-Philippe Collet; Martin Czerny; Marco De Carlo; Sebastian Debus; Christine Espinola-Klein; Thomas Kahan; Serge Kownator; Lucia Mazzolai; A Ross Naylor; Marco Roffi; Joachim Röther; Muriel Sprynger; Michal Tendera; Gunnar Tepe; Maarit Venermo; Charalambos Vlachopoulos; Ileana Desormais Journal: Eur Heart J Date: 2018-03-01 Impact factor: 29.983
Authors: Alireza Karimi; Mahdi Navidbakhsh; Ahmad Shojaei; Shahab Faghihi Journal: Mater Sci Eng C Mater Biol Appl Date: 2013-02-19 Impact factor: 7.328
Authors: María A Rodríguez-Soto; Camilo A Polanía-Sandoval; Andrés M Aragón-Rivera; Daniel Buitrago; María Ayala-Velásquez; Alejandro Velandia-Sánchez; Gabriela Peralta Peluffo; Juan C Cruz; Carolina Muñoz Camargo; Jaime Camacho-Mackenzie; Juan Guillermo Barrera-Carvajal; Juan Carlos Briceño Journal: Polymers (Basel) Date: 2022-08-23 Impact factor: 4.967